<DOC>
	<DOCNO>NCT00268216</DOCNO>
	<brief_summary>The purpose study see fluticasone 500mcg/salmeterol 50mcg improve survival subject COPD also assess long term safety profile drug .</brief_summary>
	<brief_title>Survival Of Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>A multicenter , randomize , double-blind , parallel group , placebo control study investigate effect salmeterol/fluticasone 50/500mcg bd , salmeterol 50mcg bd , fluticasone 500mcg bd , deliver via DISKUS/ACCUHALER inhaler , survival subject chronic obstructive pulmonary disease 3 year treatment .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Patients COPD FEV1 &lt; 60 % predict normal baseline ( prebronchodilator ) FEV1/FVC ratio &lt; 70 % . Current exsmokers smoke history least 10 packyears . Exclusion criterion : Diagnosis respiratory disorder ( include asthma ) . Requirement long term oxygen therapy .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>mortality</keyword>
	<keyword>TORCH</keyword>
	<keyword>SERETIDE</keyword>
	<keyword>ADVAIR</keyword>
	<keyword>COPD</keyword>
</DOC>